Top Markets
Coin of the day
Liminal BioSciences Inc. Liminal BioSciences Inc.

Liminal BioSciences Inc.

LMNL
주식 순위 #38952
Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm,... Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammatory, fibrotic, and metabolic diseases, with its operations spanning Canada and the United Kingdom. Its flagship drug candidate, fezagepras (identified as PBI-4050), has successfully advanced through Phase I clinical trials. This agent, along with its related derivatives, is undergoing investigation for potential application in treating idiopathic fibrosis affecting the lungs, liver, heart, or skin, as well as various respiratory conditions. Furthermore, Liminal is advancing antagonist programs, including G-protein coupled receptor 84 (GPR84) and Oxo-eicosanoid receptor 1 (OXER1), both of which are currently in preclinical development. Formerly known as Prometic Life Sciences Inc., the company adopted the name Liminal BioSciences Inc. in October 2019. Established in 1994, its corporate headquarters are located in Laval, Canada.
주가
$8.50
마지막 동기화: 2023-09-26
시가총액
$719.10K
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
CA
거래 Liminal BioSciences Inc. (LMNL)

카테고리

Liminal BioSciences Inc. (LMNL)의 배당 수익률 기록
Liminal BioSciences Inc. (주식 심볼: LMNL)의 배당 수익률 (TTM)은 2026 기준으로 0입니다.
지난 5년 평균 배당 수익률: 0.00%
Liminal BioSciences Inc. (LMNL)의 배당 수익률 기록: 2026 ~ 2026
연도별 말 기준 배당 수익률 (TTM)
연도 배당 수익률 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 배당 수익률 (TTM)